Predictors for lower quality of life in the HAART era among HIV-infected men

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 4, 2006, Pages 470-477

  Liu, Chenglong ^a,b   Johnson, Lisette ^a   Ostrow, David ^c   Silvestre, Anthony ^d   Visscher, Barbara ^e   Jacobson, Lisa P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HAART; Predictor; Quality of life

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; BISEXUALITY; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRINKING BEHAVIOR; DRUG ABUSE; DRUG USE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEXUAL BEHAVIOR; SHORT FORM 36; SOCIAL SUPPORT; SOCIOECONOMICS; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MALE; QUALITY OF LIFE; SEXUAL PARTNERS; SOCIAL SUPPORT;

EID: 33745906983     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000225730.79610.61     Document Type: Article

References (37)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280(17):1497-1503.
3. McGinn F, Gahagan J, Gibson E. Back to work: vocational issues and strategies for Canadians living with HIV/AIDS. Work. 2005;25(2):163-171.
4. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11(12):F101-F105.
5. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(suppl 2):S96-S116.
6. Wu AW. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS. 2000;14(10):1449-1451.
7. Eller LS. Quality of life in persons living with HIV. Clin Nurs Res. 2001;10(4):401-423.
8. Johnson RJ, Wolinsky FD. The structure of health status among older adults: disease, disability, functional limitation, and perceived health. J Health Soc Behav. 1993;34(2):105-121.
9. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59-65.
10. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126(2):310-318.
11. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual and interpretation guide. Boston: The Health Institute, 1993.
12. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405-413.
13. Liu C, Ostrow D, Hu Z et al. Impacts of HIV infection and HAART use on quality of life. Qual Life Res. In Press.
14. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82-92.
15. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320-328.
16. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol. 1990;55(2):173-186.
17. Schenker EL, Hultin LE, Bauer KD, et al. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry. 1993;14(3):307-317.
18. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 2005 revision. Available at: http://aidsinfo.nih.gov. 2005.
19. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol. 2002;155(8):760-770.
20. Center for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1993;41:
21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;Vol 1:385-401.
22. Hays RD, Cunningham WE, Sherbourne CD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med. 2000;108(9):714-722.
23. Bing EG, Hays RD, Jacobson LP, et al. Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Qual Life Res. 2000;9(1):55-63.
24. Blalock AC, McDaniel JS, Farber EW. Effect of employment on quality of life and psychological functioning in patients with HIV/AIDS. Psychosomatics. 2002;43(5):400-404.
25. Worthington C, Krentz HB. Socio-economic factors and health-related quality of life in adults living with HIV. Int J STD AIDS. 2005;16(9):608-614.
26. Gange SJ, Jacobson LP, Munoz A. Parametric models to assess tracking of categorical high-risk sexual behaviour for HIV infection. Stat Med. 1996;15(21-22):2323-2336.
27. Krentz HB, Gill MJ. The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. AIDS. 2003;17(4):631-633.
28. Bastardo YM, Kimberlin CL. Relationship between quality of life, social support and disease-related factors in HIV-infected persons in Venezuela. AIDS Care. 2000;12(5):673-684.
29. Clingerman E. Physical activity, social support, and health-related quality of life among persons with HIV disease. J Community Health Nurs. 2004;21(3):179-197.
30. Murri R, Fantoni M, Del BC, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care. 2003;15(4):581-590.
31. Wilson IB, Cleary PD. Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Med Care. 1996;34(6):610-623.
32. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140(4):256-264.
33. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS. 2004;18(18):2419-2423.
34. Burgess A, Dayer M, Catalan J, et al. The reliability and validity of two HIV-specific health-related quality-of-life measures: a preliminary analysis. AIDS. 1993;7(7):1001-1008.
35. Quercia R, Garnier E, Ferre V, et al. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. HIV Clin Trials. 2005;6(2):73-80.
36. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-1614.
37. Kessler HA, Johnson J, Follansbee S, et al. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34(4):535-542.